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Congenital heart defects (CHDs) affect approximately 1% of live births and are a major 
source of childhood morbidity and mortality even in countries with advanced health-
care systems. Along with phenotypic heterogeneity, the underlying etiology of CHDs 
is multifactorial, involving genetic, epigenetic, and/or environmental contributors. Clear 
dissection of the underlying mechanism is a powerful step to establish individualized 
therapies. However, the majority of CHDs are yet to be clearly diagnosed for the under-
lying genetic and environmental factors, and even less with effective therapies. Although 
the survival rate for CHDs is steadily improving, there is still a significant unmet need for 
refining diagnostic precision and establishing targeted therapies to optimize life quality 
and to minimize future complications. In particular, proper identification of disease asso-
ciated genetic variants in humans has been challenging, and this greatly impedes our 
ability to delineate gene–environment interactions that contribute to the pathogenesis 
of CHDs. Implementing a systematic multileveled approach can establish a continuum 
from phenotypic characterization in the clinic to molecular dissection using combined 
next-generation sequencing platforms and validation studies in suitable models at the 
bench. Key elements necessary to advance the field are: first, proper delineation of the 
phenotypic spectrum of CHDs; second, defining the molecular genotype/phenotype by 
combining whole-exome sequencing and transcriptome analysis; third, integration of 
phenotypic, genotypic, and molecular datasets to identify molecular network contribut-
ing to CHDs; fourth, generation of relevant disease models and multileveled experimen-
tal investigations. In order to achieve all these goals, access to high-quality biological 
specimens from well-defined patient cohorts is a crucial step. Therefore, establishing 
a CHD BioCore is an essential infrastructure and a critical step on the path toward 
precision child health cardiovascular medicine.
Keywords: congenital heart defects, bio banking, whole-exome sequencing, RNA-sequencing, transcriptome, 
variants, repository
Abbreviations: CHD, congenital heart defects; lncRNA, long non-coding RNA; NGS, next-generation sequencing; 
WES, whole-exome sequencing; WGS, whole-genome sequencing; SNV, single-nucleotide variants; SNP, single nucleotide 
polymorphism; CNV, copy number variations; MEMo, mutual exclusivity modules; WGCNA, weighted gene co-expression 
network analysis.
FiguRe 1 | The congenital heart defect BioCore (CHD-BioCore) implements precision child health cardiovascular medicine. Illustration of the basic 
principle of the CHD BioCore to establish an integrated continuum between the bedside and research laboratory with synergized resources and collaborative expertise.
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iNTRODuCTiON
Congenital heart defect (CHD) is a structural abnormality of 
the heart that develops before birth, affecting approximately 1% 
of live births and is a major source of pediatric morbidity and 
mortality especially within the first year of life (1–6). The past 
five decades have witnessed spectacular advancements in diag-
nostic and surgical interventions in pediatric cardiology (1, 2). 
However, despite continuing advances in prenatal detection, 
diagnostic approach, operational procedures, and postoperative 
care, the CHD field continues to face several challenges.
Given the complexity of genetic and environmental factors 
contributing to the manifestation of CHD throughout the early and 
late stages (4–13), it is essential to set an effective and practical path 
to precision medicine for both clinical service and basic discovery. 
Herein, we propose a multilayered methodology to integrate 
phenotypic assessment, genetic diagnosis, and analysis of modify-
ing environmental factors in a model system in order to identify 
targets for prevention of the underlying defect or modification of 
the disease course. In this review, we describe the elements and 
use of personalized medicine and systems biology to accomplish 
this goal. Such integrated approach can accelerate direct translation 
from discoveries to patient-tailored clinical care and actionable 
prediction of future outcomes in CHDs (Figure 1).
CuRReNT CHALLeNgeS OF CHDs  
AT CLiNiCAL SeRviCeS
early Mortality
Approximately 5% of all newborn deaths were directly attributed 
to CHDs, with 20% of CHD-related neonatal mortality associated 
with critical forms of CHDs, defined as CHD phenotypes that 
require surgery or other immediate procedures to be performed 
within the first month of life (3, 6). Several clinical challenges 
may be at the root of this problem. First, significant efforts have 
addressed the anatomical and hemodynamic aspects of CHDs. 
However, the morphogenic events that may disrupt cardiogen-
esis remain partially understood, as are many of the molecular 
networks that drive normal heart development. Therefore, 
the mechanistic understanding to the etiology and its link to 
the phenotypic presentations remain to be further established. 
Second, how the impaired heart responds to multifactorial stress 
at birth, including the surgical stress, during early postnatal life 
is understudied at both the functional as well as the cellular/
molecular levels. Third, we continue to have large gaps in our 
current knowledge on unique features of disease progression in 
infants vs. adults and right ventricle vs. left ventricle. Importantly, 
the same underlying genetic/molecular defects can often translate 
into different severities and therapeutic responses in different 
individuals. This phenomenon may be due to environmental 
or other undetected genetic interactions (4–14). Consequently, 
CHD mechanisms need to be refined at individual and mecha-
nistic levels.
Lifelong Morbidities
Advanced surgical techniques have led to remarkable success 
in our ability to palliate or correct modest anatomical defects. 
As a result, mortality has shifted away from infancy and child-
hood toward adulthood, with a steady increase of life span 
for CHD patients (2, 3). As patients get older, acquired mor-
bidities become more frequent due to confounding complica-
tions related to the underlying cause of CHD or its treatment. 
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Accordingly, the number of patients with several comorbidities 
is rapidly increasing, including neurocognitive and social mor-
bidities. In particular, acquired heart diseases, such as coronary 
artery disease, arrhythmias, cardiomyopathy, and early heart 
failure, are frequently encountered (2). Hence, our daily clinical 
encounters nowadays are confronted with a new set of problems 
(1–3). Therefore, in parallel to technological advancement, 
there is a need for targeted therapies to optimize life quality 
and to minimize future complications. In particular, revealing 
the initial genetic/molecular defect(s) that underlie the CHD, 
beyond the function and anatomy, is essential to transform our 
clinical practice to efficient management for those patients and 
to implement preventive strategies for their families. Future 
efforts should not aim only to correct or to palliate but also to 
prevent disease progression and comorbidities. This holistic 
patient-centered management needs a systematic approach that 
includes not only skilled surgeons and astute clinicians but also 
integration with geneticists and molecular biologists with spe-
cialized expertise in cardiovascular development, physiology, 
and pathobiology.
Phenotypic/genotypic Heterogeneity  
of CHDs
During the earliest steps of cardiogenesis, remote developmental 
signals and local environmental stimuli contribute to the devel-
opment of a functional circulation and any significant pertur-
bation may produce a maldeveloped heart (7–14). However, 
dissecting the genetic vs. environmental partition in the patho-
genesis of CHDs faces many challenges: first, the phenotypic 
presentations of CHDs are highly heterogeneous, and so are the 
underlying etiologies. Second, like many other complex birth 
defects, the pathogenesis of CHDs has a major genetic origin. 
However, the recurrence risk within families is minimal with 
incomplete penetrance and variable expressivity (1–5). Third, 
genomic studies of CHDs have revealed remarkable genetic com-
plexities (5, 14) including, chromosomal lesions, translocations, 
gene amplifications, single-nucleotide variants (SNVs), copy 
number variations (CNVs), and mutations of the key regulatory 
genes that drive cardiogenesis (4–14). In terms of chromosomal 
defects, trisomy 21, 13, and 18 cause together around 5–6% of 
CHD cases with trisomy 21 being the most common (15). Other 
types of chromosomal imbalance may occur at lower rates 
including DiGeorge syndrome, a microdeletion of the long arm 
of chromosome 22 (22q11) (16). Other less recurrent genomic 
lesions, including a microduplication of the long arm of chromo-
some 1 (1q21) (17), or the short arm of chromosome 8 (8p23), 
have been shown to lead to CHD. More recently, a significant 
genetic association mapped to a 200-kb region on chromosome 
20q11 was identified in a genome-wide case–control association 
study (18). Nevertheless, a child with any of these chromosomal 
abnormalities may have a normal heart, and there is wide pheno-
typic variation among those with CHDs. Beyond chromosomal 
defects, studies of rare Mendelian forms of familial CHDs have 
revealed numerous monogenic mutations and an expanding list 
of point mutations of certain genes. For example, mutations of 
β-myosin heavy chain (MYH7) are associated with increasing 
atrial septal defects (19). TBX5 and GATA4 mutations produce 
both atrial and ventricular septal defects (20), and NKX2-5 shows 
links to septal defects and electrical conduction abnormalities 
in heart (21). However, mutations in these genes could be found 
to a lower extent in the more common sporadic form that accounts 
for 70% of CHD cases.
Although their important roles in cardiac development have 
been demonstrated (22, 23), the newly emerging contributors 
to human functional genome, such as splice site mutations, 
non-coding RNAs, including the long non-coding RNAs (lncR-
NAs) and the micro RNAs, have been studied far less. Indeed, 
the lncRNAs and the regulatory elements that reside in the non-
coding DNA have recently emerged as important players in the 
genetic field of cardiac development and defects (4, 24, 25).
Other Contributing Factors
The evident phenotypic heterogeneity and the variable expres-
sivity, even with the same underlying genetic mutation, indicate 
that the CHD phenotype is likely contributed by multiple genetic 
and environmental perturbations. This idea is most supported 
by an increased risk of CHDs associated with certain environ-
mental alterations during gestation, including maternal illness 
and medications, folate deficiency, obesity, diabetes, and alcohol-
ism (13, 26, 27). Some of these perturbations may alter cardiac 
development in a manner that may not be clinically evident at 
birth, but may result in increased susceptibility to cardiac prob-
lems after birth, or increasingly with age. Other than potential 
toxic and teratogenic effects, these environmental factors may 
turn on complex epigenetic mechanisms, encompassing DNA 
methylation, histone modifications (28–32), or the non-coding 
regulatory elements such as enhancers, promotors, and lncRNAs 
(4, 24, 25). Identifying such putative factors and mechanisms 
could provide novel disease modifiers, biomarkers for diagnos-
tics, and targets for prevention.
The cardiovascular health is significantly affected by 
placental microenvironment. The so-called heart–placenta 
axis maintains  the synchronized development and growth of 
both organs. However, the factors that drive this intact axis 
or modify these tightly synergized processes during early 
embryonic stages remain poorly understood (13). It has been 
shown that the placental volume and blood flow are major 
determinants of early cardiac output and fetal organ growth 
and that placental abnormalities during gestation of the 
fetus with a CHD have deleterious effects on the outcome of 
pregnancy, including spontaneous abortion, premature birth, 
and poor prognosis (33, 34). In a previous study (35), we have 
shown significant impact on the fetoplacental hemodynamics 
and fetal cardiac function resulting from intrauterine growth 
retardation secondary to maternal caloric restriction initiated 
during the second trimester. Importantly, the reduction of 
placenta volume and fetal-placental circulatory function was 
associated with suppression of placental glucose and leucine 
transport mechanisms.
Coordinated development and function is a highly regulated 
process during each cardiac cycle and throughout the life span 
of the individual. Mechanotransduction of blood flow forces 
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in organized 3D networks orchestrates cardiac development to 
match the functional demands. It has been shown that changes 
in the retrograde flow during early cardiogenesis, can lead to 
the progression of cardiac valve defects. Altered hemodynamic 
status can also influence the development of cardiac cushions, 
which are valve progenitors (13). The contribution of impaired 
hemodynamics to the progression of valve and cushion defects 
has been modeled in Quail embryos with neural crest cell 
(CNCC) ablation, however, the exact mechanism remains to be 
established (36).
Literature evidence (37–39) on human and mouse has revealed 
that folate (folic acid, FA) deficiency, the mood-stabilizing 
drug lithium (Li), or alcohol exposure can all elevate plasma 
homocysteine (HCy) and induce cardiac and placental defects. 
These effects implicate the canonical Wnt/β-catenin signaling 
and the mediating transcription regulators Hex and Islet-1 in 
cardiogenic crescent development during early cardiogenesis and 
their potential role in CHDs. While the outflow tract defects are 
associated with elevated HCy, maternal Li therapy is associated 
with Ebstein’s anomaly of the tricuspid valve. Importantly, further 
evidence suggests that these defects can be prevented by efficient 
FA supplementation (39). Hence, evaluating the the genetic vari-
ations of folate metabolism pathways would likely provide cues 
for prevention.
More recent evidence has demonstrated that lipid metabo-
lism is also altered after alcohol ingestion in association with 
folate deficiency and type I diabetes (40). Interestingly, the 
lipid-related alterations, including fatty acid oxidation, are 
more predominant in male compared to female embryos, 
suggesting a gender bias. It is well known that gender influ-
ences the clinical presentation and the management of certain 
acquired cardiovascular diseases, such as coronary artery 
diseases. Gender differences also exist in the arrhythmogenic 
risk in patients with inherited or acquired long QT syndromes 
(41). Likewise, gender differences are also appreciated in 
CHDs. One such example is that bicuspid aortic valve has 
a male predominance of 3 to 1 (42, 43). In addition, several 
population-based studies have shown that more severe types 
of CHDs are more prevalent in male neonates and those male 
newborns undergo more severe types of surgeries than the 
female counterparts (44). Some animal studies also indicate 
a role for embryonic gender in how genes are expressed. 
Whether the potential role of gender is dictated by the sex 
hormones or driven by difference in genetic susceptibility or 
epigenetic influence between males and females during early 
embryogenesis requires further studies. In short, more mecha-
nistic investigations are essential to inform CHD management 
and strategy for prevention.
CuRReNT PROgReSS AND LiMiTATiONS 
OF CHD ReSeARCH
Biological Complexity and gaps  
of Knowledge
Elegant developmental and genetic studies over the past two 
decades have revealed the core transcription factors that drive 
the key transcriptional programs during heart morphogenesis, 
and demonstrated that the perturbations of these factors result 
in cardiac malformation, thereby, revealing important triggers 
underlying CHDs (5–11). Consequently, causative genes were 
identified, animal models were developed, and new diagnostic 
and therapeutic modalities were investigated. Collectively, 
the acquired knowledge has reflected new insights to improve 
clinical management, which was further empowered by the 
improvement of physiological monitoring, diagnostic imaging, 
and surgical applications in CHDs (44–47). However, these 
approaches mostly focused on observed anatomy, functional 
indices, or hemodynamic defects, but rarely involved insight at 
molecular and cellular levels. Further, when the disease under 
study has heterogeneous phenotypes and complex etiological 
components, it becomes much more difficult to dissect out the 
contributing factors and to distinguish between causation and 
correlation. For instance, just recently, we started to understand 
why a child has a septal defect, while one of the siblings needs a 
pacemaker.
The big problem that lies behind every individual CHD 
patient is to determine what the proper genetic model should 
be (if any). If analysis from family (familial) or parents (de novo 
recessive) is informative, one can fine-tune the genetic analysis 
based on the pedigree/familial knowledge. However, for most 
of the patients, this is not the case. The most likely scenario is 
that multiple genetic and epigenetic factors interact in any given 
patient with a CHD, explaining the complex trait character and 
presentation seen in most cases.
Systematic gaps between the Clinic  
and the Bench
Given such overwhelming complexity, it is a challenge to 
continue on the trajectory of success in scientific discoveries 
and clinical advancement unless our approaches to CHDs are 
operated as a continuum allowing close integration between 
the clinic and the bench. Moving forward, a new multileveled 
approach should be implemented. Techniques designed to, 
specifically, address genetically complex diseases will provide 
the greatest hope to unravel these clinically important myster-
ies. Defining CHD cohorts will provide unique opportunities to 
transform the insight from bedside physiologic understanding 
and bench side basic science discoveries to risk stratification 
and patient management based on the causes of the disease. 
Utilizing molecular phenotyping and targeted genetic screening 
will allow the identification of deleterious genetic mutations. 
Developing new strategies to explore the contribution of the 
environmental and epigenetic modulators and gene modifiers 
in CHDs and carrying out validation studies in suitable disease 
models, including patient specific induced pluripotent stem cells 
(iPSCs) and animal models generated by novel genome editing 
tools, will allow establishing the causality. Finally, knowledge of 
the causal determinants will provide a framework to understand 
CHDs as a continuum from malformation to ventricular failure, 
from cardiac hypertrophy to arrhythmia, presenting a clear 
pathomechanistic explanation from the clinical phenotype to 
therapeutic response, future outcomes and potential models for 
early prevention (Figure 2).
FiguRe 2 | The congenital heart defect BioCore (CHD-BioCore): strategy and frame work. Illustration of the strategic framework for the CHD BioCore:  
(1) Proper delineation of the phenotypic spectrum of CHDs. (2) Defining the molecular genotype/phenotype by combining whole-exome sequencing (WES) and 
transcriptome analysis. (3) Integration of phenotypic and molecular datasets to identify distinct molecular function networks associated with CHD phenotypes.  
(4) Integration of genomic data by mapping the putative variants to the molecular networks for mutation prioritization or pathway identification. (5) Mechanistic 
validation in relevant disease models and human induced pluripotent stem cells (iPSCs) for translational application.
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NeXT-geNeRATiON SeQueNCiNg (NgS) 
TeCHNOLOgY iN CHD FieLD: 
ADvANCeMeNTS AND CHALLeNgeS
Our ability to perform structural and functional genomic studies 
has been revolutionized with the advent of NGS technologies. 
The rapidly falling total cost of whole-exome sequencing (WES) 
and RNA-sequencing (RNA-seq), and in the future whole-
genome sequencing (WGS), makes NGS more affordable to 
approach CHDs both in clinic and at the bench. Nevertheless, 
along with tremendous advancement, several challenges have 
arisen with each technique. Therefore, the limitations of each 
of these individual approaches in detecting novel, potentially 
disease-causing, variants should be considered.
whole-exome Sequencing
As most of known disease-causing mutations reside within protein-
coding regions, the sequencing of the exome (the entire set of all 
exons in the human genome) has been widely and successfully 
applied, both for clinical and investigative studies (48–56). WES 
has been employed for the identification of heritable germline 
mutations underlying Mendelian disorders (51), somatic muta-
tions in cardiomyopathies, de novo mutations in CHDs, and other 
complex birth defects. Compared to SNP (single-nucleotide poly-
morphism) microarray, WES has higher sensitivity and specificity 
for detecting single-nucleotide variants than small insertions and 
deletions (indels). In addition, by using the depth of coverage from 
mapped short-sequence reads and appropriate bioinformatics tools 
(54), WES can detect copy number variations (CNVs), but it is not 
the method of choice. These properties make WES more robust 
to study complex disorders with genetic and phenotypic hetero-
geneity such as CHDs, even for rare and sporadic cases. However, 
moving beyond the coding regions, research on CHDs will benefit 
tremendously from replacing WES eventually with WGS (53–55), 
particularly, for the detection of pathologic CNVs and altered 
functional non-coding elements, when the sequencing cost of the 
whole genome becomes more affordable in the near future, using 
better algorithms of mapping the non-coding region and longer 
sequence reads generated by NGS technologies.
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In terms of cost, applying WES studies is now more affordable 
for application in CHDs diagnostics and research studies, with 
several advantages over the laborious conventional targeted 
sequencing of candidate genes, in particular when performed 
in trios. However, compared with WGS, additional exome-
enrichment steps are required for WES, adding to the overall 
cost. In addition, the incomplete capture of some exons and 
variable sequencing depth could potentially lead to false-negative 
results and difficulties in detecting CNVs. In terms of sequencing 
depth, similar to WGS, an average sequencing depth of 30–50× 
for WES of genomic DNA is usually sufficient to detect most 
germline SNVs accurately (51, 52). However, greater sequencing 
depth would be required to detect somatic point mutations 
in order to account for tissue contamination and genetic 
heterogeneity within the tissue. Further, the use of WES as a 
diagnostic tool continues to face technical hurdles and ethical 
issues involved in adopting this approach in clinical practice for 
CHDs. Specifically, analyzing the large amount of sequencing 
data that typically generates >30,000 genetic variants per exome 
is time and effort consuming. Thus, a robust variant-filtering 
pipeline must be generated to identify putative disease-causing 
variants for CHDs population or a particular subcohort. After 
completing several bioinformatics and filtering steps including 
identifying the non-synonymous coding variants, one approach 
is to measure the average frequency of “new variants” per gene 
across the genome, as determined by comparing the newly 
sequenced exomes to the common variation found in dbSNP. 
Challenges to such approach will arise as the finding is general-
ized to other CHD subpopulations or phenotypes. In addition, 
as the number of sequenced exomes rises, dbSNP will carry 
overwhelming number of uncommon variants. At present, new 
population-based databases are available such as the Genome 
Aggregation Database, also known as the Exome Aggregation 
Consortium in its first phase, which provide the first large-scale 
public exome CNV variant dataset based on ~60,000 human 
exomes exclusively (54, 55). More comprehensive lists of these 
and other recommended databases are available from the 
American College of Medical Genetics and Genomics (ACMG).
New statistical metrics are required to distinguish false 
positives from true signals and to account for locus and etiologic 
heterogeneity, which may often be underrecognized. In terms of 
the accuracy of variant detection, the NGS platforms generally 
have higher raw base reading error rates than traditional Sanger 
methods. Therefore, although WES technologies have greater 
specificity to detect both germline and somatic SNVs, further 
validation using Sanger sequencing remains a common practice. 
Finally, considerable ethical concerns (56) and debates remain 
unresolved, including interpretation, reporting, and disclosure of 
findings at standard level of diagnostic test accuracy.
whole-genome Sequencing
At present, WGS is the most comprehensive tool for genome-wide 
variant identification, ranging from SNVs and small indels to 
larger structural rearrangements, covering the coding sequences 
as well as the non-coding regions. Compared to WES, imple-
menting WGS brings important additional advantages to the 
CHD field. Other than uncovering potentially functional lncRNAs 
and important gene regulatory elements such as promoters and 
enhancers, CNVs could be readily detected by WGS, thereby, 
overcoming notoriously difficult limitations of WES (57–59).
The CNV is defined as a stretch of DNA, longer than 1 kb, 
which presents in the genome with an abnormal number of cop-
ies. The CNVs can constitute large deletions and duplications, 
as well as unbalanced translocations (54). In WGS data, large 
deletions can be easily detected by the same paired-end methods 
for detecting moderately sized deletions. However, large duplica-
tions are more difficult to detect, as there is no single read or read 
pair spanning the insertion. Detecting large insertions could be 
achieved using one of the split-read methods such as Pindel, 
which uses a pattern-growth approach to detect breakpoints 
at which the sequenced genome diverges from the reference. 
These methods, including discordant paired-end and split-read, 
generally do not perform well for CNV detection from WES data 
or targeted-capture sequence data due to the increased GC bias 
inherent to targeted-capture data and the discontinuous nature 
of exome sequencing as well as the difficulties in localizing the 
breakpoints. In this case, algorithms that examine the sequence 
depth of coverage are the primary means for detecting CNVs. 
Several software packages have been developed to address these 
issues (54, 55). However, because of the small size of targets in 
typical exome-capture data, many current algorithms for CNV 
detection require either a paired normal sample or a panel of 
population controls. Further improvements of these methods are 
required.
Together, WGS is the ultimate approach for genetic testing 
in CHD precision medicine. However, it will still take much 
more efforts before it becomes a standard practice in clinical 
setting. Many challenges are yet to be resolved including large 
sample size requirement, financial cost, and current limitation in 
interpretation of variants detected in non-coding regions. In the 
meanwhile, it should be recognized that WES provides an essen-
tial stepping stone toward implementing WGS. Implementing 
and refining the knowledge acquired from population databases 
for both pathogenic and benign CNVs identified in WES and 
WGS data will be crucial for developing effective strategies to 
interpret clinically relevant variants. Moving forward, analyzing 
database generated from the 1000 Genome project will provide 
new insights into the nature and extent of human genetic 
variation, leading to optimized variants detection, filtering, and 
prioritization (59).
incidental and Secondary Findings  
from weS/wgS
Variants may be detected during the course of clinical WES/WGS 
that are not directly relevant to the primary clinical indications of 
the patient, so-called “incidental” findings. To address such vari-
ants, the ACMG has provided guidelines (60–62), which initially 
recommended that clinical laboratories report any known or 
suspected pathogenic variants detected in any one of a list of 56 
genes regardless of patient age. However, these guidelines have 
since been revised (62) to allow patients to opt out of receiving 
these types of results, and the term incidental findings has been 
formally replaced by secondary findings, which reflects a desire for 
laboratories to actively search for these types of variants during the 
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process of clinical testing. While some laboratories have chosen 
to adhere closely to the guidelines, other clinical laboratories 
have chosen to keep these variants as true incidental findings. 
Therefore, the consent for genomic analysis should be explicit, 
with reference made in the consent process to the possibility of 
incidental findings. It is also important that both the patients 
and the ordering physicians understand the laboratory specific 
approach to incidental/secondary variant reporting and are 
aware of the possibility that incidental/secondary findings will 
appear on WES/WGS report if a patient has opted and indicated 
to receive them on the informed consent form provided by the 
clinical laboratory.
Most of the recommended 56 genes involve autosomal domi-
nant cancer predisposition syndromes, one such example being 
BRCA1 that predisposes an individual to breast cancer, when a 
referral to an oncologist may be necessary.
For obvious reasons, however, handling the issue of inci-
dental/secondary findings in children is far more complex and 
requires careful considerations of more sensitive issues (60–62). 
Important concerns have been raised regarding. (1) The potential 
of emotional harm of labeling a child as being at risk to develop 
a condition years into the future. (2) The potential medical 
benefits to the child’s parents of receiving certain information 
(e.g., BRCA1 and cancer predispositions). (3) The need to preserve 
the child’s autonomy and rights regarding her/his future ability 
not to have information about their own genetic constitution. 
One approach to address these issues is to accept the disclosure 
of the minimum package of important information (the list of 
56 genes) as per the ACMG recommendations but no other 
information until the subject can make his/her own decisions as 
a competent adult. Nevertheless, consensus has yet to be made 
for more complex scenarios, such as genetic testing of a fetus, 
newborn screening, later-onset neurodegenerative diseases, 
psychiatric disorders, and cardiology disorders associated with 
sudden death susceptibility.
RNA-seq for Molecular Phenotyping
As with WES and WGS, RNA-seq is a genome-wide approach 
and a powerful information-generating NGS tool. Hence, it 
would be very applicable to diseases characterized by genetic 
and phenotypic heterogeneity such as CHDs (63, 64). The tran-
scriptome of a given tissue represents a complete set of the tran-
scribed genome and encompasses all the transcripts, including 
the protein-coding mRNAs and the non-coding RNAs such as 
miRNAs and lncRNAs (65). Further, by illustrating the quantity 
and expression patterns of thousands of genes simultaneously, 
RNA-seq provides a dramatic increase in our knowledge of the 
transcriptional landscape and regulation, including insight into 
functional pathways and regulation of biological processes of 
coordinated genes during development, under different condi-
tions and in different disease phenotypes. Furthermore, RNA-seq 
allows determination of the transcriptional structure of genes, in 
terms of their transcription start sites, splicing patterns and other 
posttranscriptional modifications (66), in addition to allele-
specific expression in CHD (67) and fusion genes secondary to 
chromosomal rearrangements (68). Moreover, several RNA-seq 
methods have been developed to specifically sequence the 3′ end 
region of transcripts, allowing the discovery of alternative 
polyadenylation sites (69). Likewise, several RNA-seq analysis 
methods of reads covering exon–exon junction have facilitated 
examining alternative splicing events (65). Finally, RNA-seq 
also allows detection of SNPs in transcripts by comparing them 
to a reference transcriptome and quantifying the modification 
in expression levels of each transcript in affected population 
compared to control. A particular advantage of such application 
is allowing the discovery of SNPs in the non-coding sequences, 
including the lncRNAs (63, 64). Nevertheless, relative advan-
tages and limitations also exist in applying transcriptome stud-
ies solely in the context of variant detection. In particular, the 
challenge of detecting mutations in completely untranscribed 
genes (null mutation) using this approach must be appreciated. 
Further, the transcriptome is tissue/cell specific and may vary 
with time; hence, the transcriptome of a specific tissue only 
partially reflects the exome (70). Another critical challenge to 
the detection of variants using RNA-seq is the considerable 
variability in transcript expression levels, which can be mitigated 
by increasing the sequencing depth. However, the sequencing 
depth or coverage of RNA-seq is difficult to be estimated, given 
the potential coverage of different isoforms for the same gene 
in addition to variation in transcript abundance in different 
tissue, factors that may lead to considerable noise. Further, 
the optimal number of biological replicates (71, 72) that 
would be needed to ensure a valid biological interpretation 
of the results remains unclear. Finally, RNA-seq technologies 
continue to challenge bioinformatics for the large amount of 
multilayered data.
Other Omics Platforms
The molecular characterization of a CHD phenotype could be 
furthered and enriched by adding other functional information 
derived from utilizing other omics platforms, when available, 
including the epigenome, the metabolome, and the proteome.
iMPLeMeNTiNg PReCiSiON MeDiCiNe  
iN CHD: THe CONgeNiTAL HeART 
DeFeCT-BiOCORe (CHD BioCore)
For implementing a path to precision child health cardiovascular 
medicine, it is important to stratify the phenotypic spectrum of 
each CHD into subcohorts, based on structural, physiological, 
and functional parameters, delineate the distinct genotype 
associated with each subphenotype (subcohort) utilizing the 
power of NGS (WES, WGS), establish the pathogenic molecular 
signature that discriminates the extreme ends of each subcohort 
by implementing RNA-seq and other omics data when avail-
able (methylome, proteome, and metabolome). The integration 
among these key resources by employing systems biology tools 
is an auxiliary step. An important infrastructure to achieve 
these steps requires creation of a continuum from the clinical 
presentation, hemodynamic indices, and physiological param-
eters, to genomic determinants and gene expression landscape. 
Therefore, direct access to biological specimens is indispensable 
(Figure 3).
FiguRe 3 | The congenital heart defect BioCore (CHD-BioCore): organization and network. Illustration of the central components of an impactful CHD 
BioCore for integrated multisystem approach: (1) The Clinical Registry. (2) The Bio Banking Repository. (3) The Genomic Depository. The key elements and resources 
for each component as well as the integration among them by implementing systems biology approach were also illustrated.
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The Congenital Heart Defect BioCore 
(CHD BioCore)
Availability and quality of heart tissue specimens from pediatric 
patients with CHDs with well-defined phenotypes is the rate-
limiting factor in any effort to achieve clinically relevant scientific 
advances in the CHD field. Hence, establishing a CHD BioCore 
is an invaluable infrastructure to accelerate scientific discovery 
and clinical translation by synergizing expertise from a collabo-
rative team from different departments with combined clinical 
and research expertise. The BioCore also serves to interact with 
other CHD network member institutes nationwide and with the 
Pediatric Cardiac Genomics Consortium.
The CHD BioCore Components
An impactful CHD BioCore should have three central and 
complementary components: (1) CHD Clinical Data Registry. 
(2) CHD Bio Banking Repository. (3) CHD Genomic Data 
Depository.
CHD Clinical Data Registry
Defining CHDs cohort and clinical pool is the first priority 
for achieving comprehensive delineation of CHD phenotypes. 
Simple and cost free enrollment process and open eligibility 
criteria need to be utilized to achieve large-scale CHD popula-
tion without any restriction on ethnic backgrounds, sex, or age. 
All efforts should be made to identify familial cases and enroll 
other siblings and extended family members, including healthy 
and affected individuals. Printed materials and simple pamphlets 
(brochures) containing descriptive or advertising material can be 
utilized to facilitate recruitment.
Clinical data collection should be initiated through subject 
and family interviews in conjunction with retrieving medical 
record information including hospital course, surgical proce-
dures, and medical interventions. The data should be stored on 
structured electronic forms in the CHD clinical data registry. 
All data should be individually coded before storage. The study 
code will allow linking the data to the corresponding subject 
within the CHD BioCore cohort. Pertinent clinical data registry 
collection includes (1) Demographic data. (2) Detailed cardiac, 
medical, surgical, and developmental history. (3) Review of 
systems including dictating presence of associated syndromic 
features. (4) Clinical genetic tests and results. (5) Detailed pre-
natal course, prenatal genetic screening, fetal physiologic profile, 
hemodynamic parameters, and imaging results. (6) Detailed 
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maternal obstetric history including, maternal medical illness, 
and potential therapeutic and environmental exposure, such as 
Li ingestion, maternal diet, the status of folate supplement, and 
lipid profile. (7) Detailed family history and three-generation 
family pedigree. (8) Cardiovascular imaging data that may allow 
precise delineation of CHDs anatomy. (9) Denominated disease 
course, perioperative parameters, subsequent complications, 
and associated morbidities, such as developing coronary artery 
disease, metabolic syndrome, and neurological and cognitive dis-
orders that is essential for future disease prediction. (10) Follow- 
up questionnaire that investigates cardiac and non-cardiac medi-
cal and surgical events, medication usage, and neurodevelop-
mental status. (11) Finally, in addition to affected patients (index 
cases), the BioCore enrollment and the data collection process 
should include healthy twins, siblings, extended family mem-
bers, and control volunteers. The clinical registry data should be 
reevaluated periodically in view of the newly acquired research 
discoveries to explore potentials for translation and to improve 
outcomes. A study coordinator with specific training in large data 
management may assist in patient enrollment in a genetic study 
and ensure the data completion and accuracy.
CHD Bio Banking Repository
Proper collection, coding, and bio banking of the biological 
specimens in a timely, sensitive manner is imperative to achieve 
precise molecular and cellular signature. Proper procurement 
and annotation of remnant human tissue samples provides 
critical resources for gene discovery and translational research. 
Rapid and coordinated processing and storage of biological 
specimens can allow presenting a snapshot of protein and gene 
expression, genetic and epigenetic alterations, protein and 
enzyme activity, and/or cellular and tissue architecture through 
collecting: (1) Specimens from cardiac tissue serve to perform 
molecular cellular phenotyping, transcriptomic, and proteomic 
studies. (2) Specimens from fetal/embryonic cardiac tissue 
obtained from abortion and fetal demise cases. (3) Blood/urine/
saliva samples from index subjects and from parents and affected 
family members to obtain genomic DNA for molecular genet-
ics and genomic studies including WES/WGS. (4) Specimens 
from the placenta and the cord tissues, and cord blood samples. 
(5) Skin biopsy and blood samples collected from index cases 
and parents to generate human iPSCs. (6) Disease-specific 
human iPSCs derived from white blood cells to be utilized for 
mechanistic validation and testing new therapies. (7) Control 
samples. A potential resource for obtaining control specimens 
is the heart transplant donors and other healthy donors who 
died because of a non-cardiac reason. However, this resource 
may be challenging with obvious difficulties including the com-
plexity of the informed consent process. Therefore, deriving the 
hiPSCs from the white blood cells or the skin fibroblasts from 
affected individuals as well as healthy family members and other 
control participants is an essential and efficient solution.
CHD Genomic Data Depository
Achieving molecular characterization of CHD genotypes is 
essential to study CHDs mechanism. The CHD genomic data 
depositary is an essential component to build and enrich the 
CHD BioCore. The raw datasets generated from WES/WGS/
RNA-seq and other omics studies of CHDs cohort should be 
deposited in the CHD Genomic Data Depository to facilitate 
comparative analysis, network construction, and integration with 
clinical and experimental data as we have detailed in Section “The 
CHD BioCore Operation.”
The CHD BioCore Operation
In order to dissect the underlying complexity and biological 
heterogeneity of CHDs, integrating the phenotypic data, the 
molecular signature, and the genomic background is both 
essential and challenging. In particular, extracting biologically 
relevant targets for clinical intervention and gene discovery is 
critical.
Integrated Genomic Approach (WES and RNA-seq)
As with other large-scale sequencing projects for complex 
diseases, a key challenge in large-scale sequencing approach for 
CHDs is to distinguish putative “damaging” mutations, which 
may contribute to malformation, from “non-damaging” muta-
tions, which are functionally neutral. The second key challenge is 
to identify novel developmental pathways that may be perturbed 
by uterus environment during heart development, leading to car-
diac defect by affecting cell proliferation, apoptosis, migration, 
angiogenesis, etc. The third and particularly critical challenge is 
to transition from association and correlation to function and 
causality. Although conflicting, a number of approaches have 
addressed these challenges in other diseases, as well as in CHD 
pathobiology, attaining some degree of success (73, 74). However, 
several analytical challenges of large data rapidly emerged, requir-
ing new tools to integrate genomic information with traditional 
clinical parameters, environmental culprits, and pathological 
data in an iterative manner.
Our limited ability to interpret the functional significance 
of genetic variants requires moving from the change in gene 
sequence to the functional impact of that change, therein, 
revealing critical needs for interrogating both WES (WGS in the 
near future) and RNA-seq data (Figure 2). Such bidimensional 
genomic approach has provided efficiency in several models of 
complex disease including autism spectrum genetics, cancer, and 
long QT syndrome therapies (75–77). In particular, combining 
exome and transcriptome data has been essential for the defini-
tion of fusion genes, allelic heterogeneity, locus heterogeneity 
and splice site mutations (66, 67). Other than enhancing data 
interpretation, candidate variant selection and diagnostic preci-
sion, the inherent output of RNA-seq, including defining the 
contents and the abundance of protein-coding genes, splicing 
isoforms, and non-coding RNAs, could be utilized to a larger 
extent to study CHDs mechanisms, such as the non-coding ele-
ments and genetic modifiers.
Systems Biology Methods for Network-Oriented Data Mining
A comprehensive approach for CHDs requires sophisticated 
management and integration of giant datasets, including 
genomic, expression, cellular and molecular, environmental, 
phenotypic, and clinical datasets. Systems biology methodology 
is rapidly developing and particularly intriguing solution for 
10
Touma et al. CHDs Precision Medicine
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2017 | Volume 4 | Article 36
constructing, evaluating, and interpreting gene networks from 
large datasets, to predict the biological impact of novel signal-
ing pathways and to prioritize deleterious candidate mutations 
(78). In the current review, we take a wide definition of systems 
biology by considering a CHD in a patient as a system. In this 
context, systems biology approach is the study of the integrated 
interactions of the network(s) of genes, their variants (polymor-
phisms, rearrangements, alternate splicing, and mutations), their 
isoforms, and the molecules with which they interact to execute 
the signaling cascade or the biochemical reactions that reflect 
the function of that system that ultimately leads to the specific 
phenotype.
Data Integration Algorithm
To establish an algorithm for data integration, we propose de novo 
construction of functional networks based upon the RNA-seq 
data, and other omics data when available, by applying weighted 
gene network co-expression analysis methods (WGNCA) (78), so 
as to build both combined and phenotype specific co-expression 
networks. This approach assumes that genes with similar expres-
sion patterns across different samples share similar regulatory 
program and may function in common or similar biological 
pathways or cellular processes. In contrast the genes with different 
expression patterns across different samples may reflect differen-
tial pathway activation or altered regulation of cellular processes 
that are specific or unique to each sample. First, the molecular 
signature that defines a CHD phenotype, or a subcohort, needs 
to be characterized separately by interrogating the different lay-
ers of the transcriptome complexity derived from RNA-seq and 
constructing comprehensive biological networks from the coding 
mRNA isoforms and the non-coding RNA transcripts. Next, by 
implanting correlation statistics using a composite measure of 
module gene expression, also known as the module eigengene, 
or the first principal component, the significance of association 
between a specific module and a trait, such as a clinical pheno-
type, an environmental exposure, or a genetic mutation, could 
be calculated. This will serve to link the molecular module to the 
trait of interest. The impact of incidental confounding covariant 
could be adjusted using the regression statistics. In this manner, 
the large datasets for each clinical phenotype can be reduced into 
small groups of co-expressed genes, known as gene modules. 
Each module represents a unique and distinct co-expressed gene 
network.
Then, a preservation analysis serves to compare the modules 
that are common and those that define the traits of interest, a clini-
cal phenotype, an environmental exposure, or a genetic mutation. 
Using the spectrum of Teratology of Fallot as an example, the cases 
could be stratified clinically along a spectrum of severity based 
on their anatomical structure, such as the degree of pulmonary 
stenosis as the Z score. After constructing the modules that 
associate with each case (or a group of cases with similar degree of 
stenosis), the preservation statistics, e.g., hypergeometric overlap, 
can be used to determine the module(s) that are common vs. 
those that define each end of the spectrum (the mild, the moder-
ate, or the severe subphenotype), thereby, the putative functional 
molecular networks overlapping along the phenotypic spectrum 
and those that define each subphenotype will be constructed. 
The poorly preserved modules in each analysis may represent a 
distinct molecular signature of each subphenotype. Further, the 
corresponding hub genes, those top significant genes that highly 
correlate with the module eigengene, may represent a primary 
indicator of the network function for the subphenotype. Finally, 
the biological function of the unique hub genes or distinct network 
could be predicted using functional ontology and pathway enrich-
ment analysis methods using DAVID.
In parallel analysis, the genes affected with putative deleteri-
ous variants obtained from WES analysis should be examined 
for their biological function. Next, the candidate variants will be 
mapped to the constructed molecular networks of each subphe-
notpe. Subsequently, the highly affected genes at the expression 
level or posttranscriptional modification can be identified, allow-
ing to link to a distinct expression module, which correspond to 
a defined subphenotype, to a specific mutation of a key transcrip-
tion regulator or a hub pathway that bears an excess mutation 
burden of several genes.
An important advantage of this systems based strategy is the 
applicability to construct functional networks from multiple 
data sources, including splicing isoforms, non-coding RNAs, or 
proteomic, metabolomic, and epigenetic data, when available, as 
well as other structural, functional, clinical, and environmental 
parameters in functional modules. Therefore, this strategy pre-
sents a potential tool for determining the functional regulatory 
network, based on which, the variants selection and prioritiza-
tion will be carried out by interrogating the DNA data obtained 
from WES/WGS to be validated in mechanistic studies. In this 
scenario, this precise phenotypic/genotypic characterization 
at the molecular functional level will tremendously empower 
pinpointing and prioritization of the candidate damaging vari-
ants for mechanistic studies and future translation to diagnostic 
applications and targeted therapy.
In a recent study (24), we demonstrated the utility of systems 
biology for interrogating the coding and non-coding transcripts 
derived from RNA-seq data to detect functionally important 
(even novel unannotated) lncRNAs potentially implicated in 
cardiac maturation and CHDs phenotypes. These lncRNAs 
potentially interact with regulatory elements or epigenetic 
regulators to produce significant biological alterations and protein 
damages. Comprehensive systems biology models have been 
employed in autism spectrum disorders (55) and cancer biology 
(79) for integrating multilayered clinical data and genomics 
networks. Other intriguing systems based methods include the 
Integrated Personal Omics Profile (IPOP) for personal omics for 
dynamic data integration along the clinical course (80), allowing 
acquiring a comprehensive picture of detailed molecular differ-
ences between different physiological states as well as during the 
pathogenic course from onset to resolution.
Another method starts by identifying the core pathways that 
appear to be implicated in CHDs based on existing knowledge, 
and constructing gene–gene interactions pathways to merge them 
into a new expression network and then, mapping all mutated 
genes to the newly constructed network. The shortest paths con-
necting all mutated genes could be filtered from the network to 
form a subnetwork. Subsequently, the network modules could be 
analyzed to identify candidate pathways for mechanistic studies. 
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A similar approach has implicated the ciliopathy pathway in CHDs 
(81) by using WES and constructing protein–protein interaction 
networks.
Lastly, in light of the clonal nature of cell expansion in 
cardiovascular development (7) and given the majority of CHD 
cases occur on a sporadic basis with the heart being the only 
affected organ, somatic mutation may also have a significant con-
tribution to CHDs. Therefore, constructing mutual exclusivity 
modules (MEMo) (82) may serve to predict novel hub gene 
candidates from a specified gene network involving somatic 
mutations and to construct the interaction network in CHDs 
without prior information of the underlying gene–gene inter-
actions. This method is based on the “Mutual Exclusivity 
Principle” which implies that different gene mutations or alter-
ations that affect the same pathway do not tend to co-occur in 
the same patient. In this method, a gene exclusivity network 
can be constructed based on the exclusivity score, which acts 
as the weight of edge between every pair of genes. The MEMo 
are then extracted and linked to RNA-seq modules using 
specific statistical algorithms.
Integration of CHD BioCore in CHD Clinical Care and 
Research
As previously stated, the CHD BioCore infrastructure should 
be organized to synergize expertise from a collaborative team 
with combined clinical and research expertise. Specifically, 
it needs to build seamless interactions with multi-omics plat-
forms, where WES and whole transcriptome profiles can be 
accomplished and future proteomics or metabolomics can be 
implemented. The discoveries made through systems studies 
of CHD samples will need to be validated and mechanistically 
interrogated in model organisms. Mutagenesis and animal 
model studies remain needed to lend further support to the 
causality of the variants and to demonstrate the effect that 
causal variants have at phenotypic level. Model systems for 
CHD gene discovery may include (1) Cultured cells, includ-
ing primary cardiomyocytes, endothelial cells, and fibroblasts 
from developing rat or mouse hearts and hiPSCs derived from 
healthy controls and CHD patients, which may offer mechanis-
tic clues at molecular and cellular levels. (2) Zebrafish models 
combined with genome editing via CRISPR/Cas9 system, 
which offers high efficiency in vivo analysis for cardiovascular 
development. (3) Target-specific genetically engineered mouse 
models that offer in-depth analysis for functional, pathological, 
and translational validation. Such model systems can then be 
validated using appropriate pathologic, biochemical, or physi-
ologic assessments (Figure 3).
The CHD BioCore Data Sharing
As the path toward understanding CHDs progresses, knowledge 
sharing through informatics databases will accelerate the dis-
semination and validation of experimental findings.
CONCLuSiON
An effective clinical utilization of the new discoveries promises 
to guide strategic approaches toward improved future outcomes 
for CHDs but requires narrowing existing gaps between the 
laboratory bench and the clinic. The importance of dissecting 
the molecular mechanism of CHDs is at least threefolds. First, 
linking CHDs with specific genetic mutations, epigenetic or 
molecular markers, or environmental exposure can lead to dis-
ease prevention, family planning, and possible intervention prior 
to birth. Second, better knowledge of the genetic and molecular 
basis of CHDs would allow more mechanism-based, precise, and 
personalized approaches to these patients in the prenatal and 
preoperative setting. Third, with better understanding of gene–
gene interaction and gene–environment interaction involved in 
CHDs, we will be able to identify novel targets and intervention 
approaches to prevent and effectively treat the pathological 
manifestation of CHDs. Finally, establishing CHD BioCore is 
essential infrastructure serving to integrate clinical efforts and 
research innovation. We thus describe a procedure to, effectively, 
reduce observations to a focused subset of high specificity on the 
path to precision child health cardiovascular medicine.
AuTHOR CONTRiBuTiONS
Conception, design, and drafting of the manuscript: MT. 
Sub stantial contributions to the conception: BR, SN, and YW. 
Substantial contribution to the design of the work, revising the 
work critically, final approval of the version to be published, and 
agreement to be accountable for all aspects of the work in ensu-
ing that questions related to accuracy or integrity of any part of 
the work are appropriately investigated and resolved: MT, BR, 
NH, JA, JF, SN, and YW.
FuNDiNg
This work was supported by grants from National Institutes of 
Health (NIH)/Child Health Research Center (5K12HD034610/
K12) and the UCLA-Children’s Discovery Institute and Today 
and Tomorrow Children’s Fund to MT. This work is supported in 
part by NIH grants HL114437 and HL123295 to YW.
ReFeReNCeS
1. Triedman JK, Newburger JW. Trends in congenital heart disease. The next 
decade. Circulation (2016) 133:2716–33. doi:10.1161/CIRCULATIONAHA. 
116.023544 
2. Gilboa SM, Devine OJ, Kucik JE, Oster ME, Riehle-Colarusso T, Nembhard WN, 
et al. Congenital heart defects in the United States estimating the magnitude 
of the affected population in 2010. Circulation (2016) 134:101–9. doi:10.1161/
CIRCULATIONAHA.115.019307 
3. Pruetz JD, Carroll C, Trento LU, Chang RK, Detterich J, Miller DA, et  al. 
Outcomes of critical congenital heart disease requiring emergent neonatal 
cardiac intervention. Prenat Diagn (2014) 34:1127–32. doi:10.1002/pd.4438 
4. Postma AV, Bezzina CR, Christoffels VM. Genetics of congenital heart disease: 
the contribution of the noncoding regulatory genome. J Hum Genet (2016) 
61:13–9. doi:10.1038/jhg.2015.98 
5. Lalani SR, Belmont JW. Genetic basis of congenital cardiovascular malfor-
mations. Eur J Med Genet (2014) 57(8):402–13. doi:10.1016/j.ejmg.2014. 
04.010 
12
Touma et al. CHDs Precision Medicine
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2017 | Volume 4 | Article 36
6. Peterson C, Dawson A, Grosse SD, Riehle-Colarusso T, Olney RS, 
Tanner JP, et  al. Hospitalizations, costs, and mortality among infants 
with critical congenital heart disease: how important is timely detection? 
Birth Defects Res A Clin Mol Teratol (2013) 97(10):664–72. doi:10.1002/ 
bdra.23165 
7. Garry DJ, Olson EN. A common progenitor at the heart of development. Cell 
(2006) 127(6):1101–4. doi:10.1016/j.cell.2006.11.031 
8. Solloway MJ, Harvey RP. Molecular pathways in myocardial development: a 
stem cell perspective. Cardiovasc Res (2003) 58:264–77. doi:10.1016/S0008- 
6363(03)00286-4 
9. Yuan S, Zaidi S, Brueckner M. Congenital heart disease: emerging themes 
linking genetics and development. Curr Opin Genet Dev (2013) 23(3):352–9. 
doi:10.1016/j.gde.2013.05.004 
10. Chin AJ, Saint-Jeannet JP, Lo CW. How insights from cardiovascular 
developmental biology have impacted the care of infants and children with 
congenital heart disease. Mech Dev (2012) 129(5–8):75–97. doi:10.1016/j.
mod.2012.05.005 
11. Mitchell ME, Sander TL, Klinkner DB, Tomita-Mitchell A. The molecular 
basis of congenital heart disease. Semin Thorac Cardiovasc Surg (2007) 
19(3):228–37. doi:10.1053/j.semtcvs.2007.07.013 
12. Kathiriya IS, Nora EP, Bruneau BG. Investigating the transcriptional control 
of cardiovascular development. Circ Res (2015) 116(4):700–14. doi:10.1161/
CIRCRESAHA.116.302832 
13. Linask KK. The heart-placenta axis in the first month of pregnancy: induc-
tion and prevention of cardiovascular birth defects. J Pregnancy (2013) 
2013:320413. doi:10.1155/2013/320413 
14. Pierpont ME, Basson CT, Benson DW, Gelb BD, Giglia TM, Goldmuntz E, 
et al. Genetic basis for congenital heart defects: current knowledge. A scientific 
statement from the American Heart Association Congenital Cardiac Defects 
Committee, Council on cardiovascular disease in the young: endorsed by 
the American Academy of Pediatrics. Circulation (2007) 115(23):3015–38. 
doi:10.1161/CIRCULATIONAHA.106.183056 
15. Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, et al. 
Ethnicity, sex, and the incidence of congenital heart defects: a report from 
the National Down Syndrome Project. Genet Med (2008) 10(3):173–80. 
doi:10.1097/GIM.0b013e3181634867 
16. Mlynarski EE, Xie M, Taylor D, Sheridan MB, Guo T, Racedo SE, et al. Rare 
copy number variants and congenital heart defects in the 22q11.2 deletion 
syndrome. Hum Genet (2016) 135(3):273–85. doi:10.1007/s00439-015-1623-9 
17. Sun G, Tan Z, Fan L, Wang J, Yang Y, Zhang W. 1q21.1 microduplication in 
a patient with mental impairment and congenital heart defect. Mol Med Rep 
(2015) 12(4):5655–8. doi:10.3892/mmr.2015.4166 
18. Hanchard NA, Swaminathan S, Bucasas K, Furthner D, Fernbach S, Azamian MS, 
et al. A genome-wide association study of congenital cardiovascular left-sided 
lesions shows association with a locus on chromosome 20. Hum Mol Genet 
(2016) 11:2331–41. doi:10.1093/hmg/ddw071 
19. Bettinelli AL, Mulder TJ, Funke BH, Lafferty KA, Longo SA, Niyazov DM. 
Familial Ebstein anomaly, left ventricular hypertrabeculation, and ventricular 
septal defect associated with a MYH7 mutation. Am J Med Genet A (2013) 
161A(12):3187–90. doi:10.1002/ajmg.a.36182 
20. Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, 
et  al. GATA4 mutations cause human congenital heart defects and reveal 
an interaction with TBX5. Nature (2003) 424(6947):443–7. doi:10.1038/
nature01827 
21. Chung IM, Rajakumar G. Genetics of congenital heart defects: the NKX2-5 
gene, a key player. Genes (Basel) (2016) 7(2):E6. doi:10.3390/genes7020006 
22. Pereira Fernandes M, Azevedo O, Pereira V, Calvo L, Lourenço A. 
Arrhythmogenic right ventricular cardiomyopathy with left ventricular 
involvement: a novel splice site mutation in the DSG2 gene. Cardiology (2015) 
130(3):159–61. doi:10.1159/000369057 
23. Smith T, Rajakaruna C, Caputo M, Emanueli C. microRNAs in congenital 
heart disease. Ann Transl Med (2015) 3(21):333. doi:10.3978/j.issn.2305-5839 
24. Touma M, Kang X, Zhao Y, Cass AA, Gao F, Biniwale R, et  al. Decoding 
the long noncoding RNA during cardiac maturation: a roadmap for func-
tional discovery. Circ Cardiovasc Genet (2016) 9(5):395–407. doi:10.1161/
CIRCGENETICS.115.001363 
25. Rizki G, Boyer LA. Lncing epigenetic control of transcription to cardiovas-
cular development and disease. Circ Res (2015) 117(2):192–206. doi:10.1161/
CIRCRESAHA.117.304156 
26. Parnell AS, Correa A, Reece EA. Pre-pregnancy obesity as a modifier of 
gestational diabetes and birth defects associations: a systematic review. Matern 
Child Health J (2017) 21(5):1105–20. doi:10.1007/s10995-016-2209-4 
27. Leirgul E, Brodwall K, Greve G, Vollset SE, Holmstrom H, Tell GS, et  al. 
Maternal diabetes, birth weight, and neonatal risk of congenital heart defects 
in Norway, 1994–2009. Obstet Gynecol (2016) 128(5):1116–25. doi:10.1097/
AOG.0000000000001694 
28. Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, et al. De novo muta-
tions in histone modifying genes in congenital heart disease. Nature (2013) 
498(7453):220–3. doi:10.1038/nature12141 
29. Serra-Juh C, Cusc I, Homs A, Flores R, Torán N, Pérez-Jurado LA. DNA 
methylation abnormalities in congenital heart disease. Epigenetics (2015) 
10(2):167–77. doi:10.1080/15592294.2014.998536 
30. Lahm H, Schön P, Doppler S, Dreßen M, Cleuziou J, Deutsch MA, et  al. 
Tetralogy of fallot and hypoplastic left heart syndrome – complex clinical 
phenotypes meet complex genetic networks. Curr Genomics (2015) 16(3): 
141–58. doi:10.2174/1389202916666150303232520 
31. Guo T, Chung JH, Wang T, McDonald-McGinn DM, Kates WR, Hawu W, 
et al. Histone modifier genes alter conotruncal heart phenotypes in 22q11.2 
deletion syndrome. Am J Hum Genet (2015) 97(6):869–77. doi:10.1016/j.
ajhg.2015.10.013 
32. Ang SY, Uebersohn A, Spencer CI, Huang Y, Lee JE, Ge K, et  al. KMT2D 
regulates specific programs in heart development via histone H3 lysine 
4 di-methylation. Development (2016) 143:810–21. doi:10.1242/dev.132688 
33. Acharya G, Erkinaro T, Makikallio K, Lappalainen T, Rasanen J. Relationships 
among Doppler-derived umbilical artery absolute velocities, cardiac function, 
and placental volume blood flow and resistance in fetal sheep. Am J Physiol 
Heart Circ Physiol (2004) 286(4):H1266–72. doi:10.1152/ajpheart.00523.2003 
34. Acharya G, Wilsgaard T, Berntsen GKR, Maltau JM, Kiserud T. Reference 
ranges for serial measurements of blood velocity and pulsatility index at the 
intra-abdominal portion, and fetal and placental ends of the umbilical artery. 
Ultrasound Obstet Gynecol (2005) 26(2):162–9. doi:10.1002/uog.1902 
35. Ganguly A, Touma M, Thamotharan S, De Vivo DC, Devaskar SU. Maternal 
calorie restriction causing uteroplacental insufficiency differentially affects 
mammalian placental glucose and leucine transport molecular mechanisms. 
Endocrinology (2016) 157(10):4041–54. doi:10.1210/en.2016-1259 
36. Ma P, Gu S, Karunamuni GH, Jenkins MW, Watanabe M, Rollins AM. Cardiac 
neural crest ablation results in early endocardial cushion and hemodynamic 
flow abnormalities. Am J Physiol Heart Circ Physiol (2016) 311:H1150–9. 
doi:10.1152/ajpheart.00188.2016 
37. Hobbs CA, Cleves MA, Karim MA, Zhao W, MacLeod SL. Maternal folate- 
related gene environment interactions and congenital heart defects. Obstet 
Gynecol (2010) 116(2 Pt 1):316–22. doi:10.1097/AOG.0b013e3181e80979 
38. Han M, Serrano MC, Lastra-Vicente R, Brinez P, Acharya G, Huhta JC, 
et al. Folate rescues lithium-, homocysteine- and Wnt3A-induced vertebrate 
cardiac anomalies. Dis Model Mech (2009) 2(9–10):467–78. doi:10.1242/dmm. 
001438 
39. Huhta JC, Linask K. When should we prescribe high-dose folic acid to prevent 
congenital heart defects? Curr Opin Cardiol (2015) 30(1):125–31. doi:10.1097/
HCO.0000000000000124 
40. Serrano M, Han M, Brinez P, Linask KK. Fetal alcohol syndrome: cardiac 
birth defects in mice and prevention with folate. Am J Obstet Gynecol (2010) 
203(1):75.e7–15. doi:10.1016/j.ajog.2010.03.017 
41. Vink AS, Clur SB, Geskus RB, Blank AC, De Kezel CC, Yoshinaga M, et al. 
Effect of age and sex on the QTc interval in children and adolescents with type 1 
and 2 long-QT syndrome. Circ Arrhythm Electrophysiol (2017) 10(4):e004645. 
doi:10.1161/CIRCEP.116.004645 
42. Odening KE, Koren G. How do sex hormones modify arrhythmogenesis 
in long-QT syndrome? Sex hormone effects on arrhythmogenic substrate 
and triggered activity. Heart Rhythm (2014) 11(11):2107–15. doi:10.1016/j.
hrthm.2014.06.023 
43. Prakash SK, Bossé Y, Muehlschlegel JD, Michelena HI, Limongelli G, 
Della Corte A, et al. A roadmap to investigate the genetic basis of bicuspid 
aortic valve and its complications: insights from the International BAVCon 
(Bicuspid Aortic Valve Consortium). J Am Coll Cardiol (2014) 64(8):832–9. 
doi:10.1016/j.jacc.2014.04.073 
44. Atz AM, Travison TG, Williams IA, Pearson GD, Laussen PC, Mahle WT, 
et al. Prenatal diagnosis and risk factors for preoperative death in neonates 
with single right ventricle and systemic outflow obstruction: screening data 
13
Touma et al. CHDs Precision Medicine
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2017 | Volume 4 | Article 36
from the pediatric heart network single ventricle reconstruction trial. J Thorac 
Cardiovasc Surg (2010) 140(6):1245–50. doi:10.1016/j.jtcvs.2010.05.022 
45. Fratz S, Chung T, Greil GF, Samyn MM, Taylor AM, Valsangiacomo Buechel ER, 
et  al. Guidelines and protocols for cardiovascular magnetic resonance in 
children and adults with congenital heart disease: SCMR expert consensus 
group on congenital heart disease. J Cardiovasc Magn Reson (2013) 15:51. 
doi:10.1186/1532-429X-15-51 
46. Parvin Nejad S, Blaser MC, Santerre JP, Caldarone CA, Simmons CA. 
Biomechanical conditioning of tissue engineered heart valves: too much 
of a good thing? Adv Drug Deliv Rev (2016) 96:161–75. doi:10.1016/j.addr. 
2015.11.003 
47. Jacobs JP, Wernovsky G, Elliott MJ. Analysis of outcomes for congenital 
cardiac disease: can we do better? Cardiol Young (2007) 17(Suppl 2):145–58. 
doi:10.1017/S1047951107001278 
48. Majewski J, Schwartzentruber J, Lalonde E, Montpetit A, Jabado N. What can 
exome sequencing do for you? J Med Genet (2011) 48(9):580–9. doi:10.1136/
jmedgenet-2011-100223 
49. Hansen MC, Herborg LL, Hansen M, Roug AS, Hokland P. Combination 
of RNA- and exome sequencing: increasing specificity for identification 
of somatic point mutations and indels in acute leukaemia. Leuk Res (2016) 
51:27–31. doi:10.1016/j.leukres.2016.10.009 
50. Ku CS, Wu M, Cooper DN, Naidoo N, Pawitan Y, Pang B, et al. Exome versus 
transcriptome sequencing in identifying coding region variants. Expert Rev 
Mol Diagn (2012) 12(3):241–51. doi:10.1586/erm.12.10 
51. Ku CS, Naidoo N, Pawitan Y. Revisiting Mendelian disorders through 
exome sequencing. Hum Genet (2011) 129(4):351–70. doi:10.1007/s00439- 
011-0964-2 
52. Wang Z, Liu X, Yang BZ, Gelernter J. The role and challenges of exome sequenc-
ing in studies of human diseases. Front Genet (2013) 4:160. doi:10.3389/ 
fgene.2013.00160 
53. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. 
Hum Mol Genet (2010) 19(R2):R145–51. doi:10.1093/hmg/ddq333 
54. Abel HJ, Duncavage EJ. Detection of structural DNA variation from next 
generation sequencing data: a review of informatic approaches. Cancer Genet 
(2013) 206(12):432–40. doi:10.1016/j.cancergen.2013.11.002 
55. Kosmicki JA, Samocha KE, Howrigan DP, Sanders SJ, Slowikowski K, Lek M, 
et al. Refining the role of de novo protein-truncating variants in neurodevel-
opmental disorders by using population reference samples. Nat Genet (2017) 
49(4):504–10. doi:10.1038/ng.3789 
56. Helm BM, Langley K, Spangler BB, Schrier Vergano SA. Military health 
care dilemmas and genetic discrimination: a family’s experience with whole 
exome sequencing. Narrat Inq Bioeth (2015) 5(2):179–86. doi:10.1353/nib. 
2015.0059 
57. Ruderfer DM, Hamamsy T, Lek M, Karczewski KJ, Kavanagh D, Samocha KE, 
et al. Patterns of genic intolerance of rare copy number variation in 59,898 
human exomes. Nat Genet (2016) 48(10):1107–11. doi:10.1038/ng.3638 
58. Hong CS, Singh LN, Mullikin JC, Biesecker LG. Assessing the reproducibility 
of exome copy number variations predictions. Genome Med (2016) 8(1):82. 
doi:10.1186/s13073-016-0336-6 
59. The 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, 
Garrison EP, Kang HM, et al. A global reference for human genetic variation. 
Nature (2015) 526(7571):68–74. doi:10.1038/nature15393 
60. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG 
recommendations for reporting of incidental findings in clinical exome 
and genome sequencing. Genet Med (2013) 15(7):565–74. doi:10.1038/gim. 
2013.73 
61. Goddard KA, Whitlock EP, Berg JS, Williams MS, Webber EM, Webster JA, 
et al. Description and pilot results from a novel method for evaluating return 
of incidental findings from next generation sequencing technologies. Genet 
Med (2013) 15(9):721–8. doi:10.1038/gim.2013.37 
62. ACMG Board of Directors. ACMG policy statement: updated recom-
mendations regarding analysis and reporting of secondary findings in 
clinical genome-scale sequencing. Genet Med (2015) 17(1):68–9. doi:10.1038/
gim.2014.151 
63. Chepelev I, Wei G, Tang Q, Zhao K. Detection of single nucleotide variations 
in expressed exons of the human genome using RNA-seq. Nucleic Acids Res 
(2009) 37(16):e106. doi:10.1093/nar/gkp507 
64. Costa V, Aprile M, Esposito R, Ciccodicola A. RNA-seq and human complex 
diseases: recent accomplishments and future perspectives. Eur J Hum Genet 
(2013) 21(2):134–42. doi:10.1038/ejhg.2012.129 
65. Costa V, Angelini C, De Feis I, Ciccodicola A. Uncovering the complexity 
of transcriptomes with RNA-seq. J Biomed Biotechnol (2010) 2010:853916. 
doi:10.1155/2010/853916 
66. Wang J, Ye Z, Huang TH, Shi H, Jin VX. Computational methods and correlation 
of exon-skipping events with splicing, transcription, and epigenetic factors. 
Methods Mol Biol (2017) 1513:163–70. doi:10.1007/978-1-4939-6539-7_11 
67. McKean DM, Homsy J, Wakimoto H, Patel N, Gorham J, DePalma SR, et al. 
Loss of RNA expression and allele-specific expression associated with congen-
ital heart disease. Nat Commun (2016) 7:12824. doi:10.1038/ncomms12824 
68. Arsenijevic V, Davis-Dusenbery BN. Reproducible, scalable fusion gene 
detection from RNA-seq. Methods Mol Biol (2016) 1381:223–37. doi:10.1007/ 
978-1-4939-3204-7_13 
69. Fox-Walsh K, Davis-Turak J, Zhou Y, Li H, Fu XD. A multiplex RNA-seq 
strategy to profile poly(A+) RNA: application to analysis of transcription 
response and 3′ end formation. Genomics (2011) 98(4):266–71. doi:10.1016/j.
ygeno.2011.04.003 
70. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportuni-
ties. Nat Rev Genet (2011) 12(2):87–98. doi:10.1038/nrg2934 
71. Gu X. Statistical detection of differentially expressed genes based on RNA-seq: 
from biological to phylogenetic replicates. Brief Bioinform (2016) 17(2):243–8. 
doi:10.1093/bib/bbv035 
72. Liu Y, Zhou J, White KP. RNA-seq differential expression studies: more 
sequence or more replication? Bioinformatics (2014) 30(3):301–4. doi:10.1093/
bioinformatics/btt688 
73. LaHaye S, Corsmeier D, Basu M, Bowman JL, Fitzgerald-Butt S, Zender G, 
et al. Utilization of whole exome sequencing to identify causative mutations 
in familial congenital heart disease. Circ Cardiovasc Genet (2016) 9(4):320–9. 
doi:10.1161/CIRCGENETICS.115.001324 
74. Grace AA, Roden DM. Systems biology and cardiac arrhythmias. Lancet 
(2012) 380(9852):1498–508. doi:10.1016/S0140-6736(12)61462-7 
75. Sieberts SK, Schadt EE. Moving toward a system genetics view of disease. 
Mamm Genome (2007) 18(6–7):389–401. doi:10.1007/s00335-007-9040-6 
76. Moreno-Moral A, Petretto E. From integrative genomics to systems genetics 
in the rat to link genotypes to phenotypes. Dis Model Mech (2016) 9(10): 
1097–110. doi:10.1242/dmm.026104 
77. Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP. An integra-
tive data science pipeline to identify novel drug interactions that prolong the 
QT interval. Drug Saf (2016) 39(5):433–41. doi:10.1007/s40264-016-0393-1 
78. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation net-
work analysis. BMC Bioinformatics (2008) 9:559. doi:10.1186/1471-2105-9-559 
79. Xu X, Zhou Y, Miao R, Chen W, Qu K, Pang Q, et al. Transcriptional modules 
related to hepatocellular carcinoma survival: coexpression network analysis. 
Front Med (2016) 10(2):183–90. doi:10.1007/s11684-016-0440-4 
80. Li-Pook-Than J, Snyder M. iPOP goes the world: integrated personalized 
omics profiling and the road toward improved health care. Chem Biol (2013) 
20(5):660–6. doi:10.1016/j.chembiol.2013.05.001 
81. Li Y, Klena NT, Gabriel GC, Liu X, Kim AJ, Lemke K, et al. Global genetic 
analysis in mice unveils central role for cilia in congenital heart disease. Nature 
(2015) 521(7553):520–4. doi:10.1038/nature14269 
82. Ciriello G, Cerami E, Aksoy BA, Sander C, Schultz N. Using MEMo to dis-
cover mutual exclusivity modules in cancer. Curr Protoc Bioinformatics (2013) 
41:8.17.1–8.17.12. doi:10.1002/0471250953.bi0817s41 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Touma, Reemtsen, Halnon, Alejos, Finn, Nelson and Wang. 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) or licensor are credited and that the 
original publication in this journal is cited, in accordance with accepted academic 
practice. No use, distribution or reproduction is permitted which does not comply 
with these terms.
